CN103784244B - A kind of intrauterine implant - Google Patents
A kind of intrauterine implant Download PDFInfo
- Publication number
- CN103784244B CN103784244B CN201310003855.5A CN201310003855A CN103784244B CN 103784244 B CN103784244 B CN 103784244B CN 201310003855 A CN201310003855 A CN 201310003855A CN 103784244 B CN103784244 B CN 103784244B
- Authority
- CN
- China
- Prior art keywords
- pastille
- diaphragm
- support
- intrauterine
- implant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F6/00—Contraceptive devices; Pessaries; Applicators therefor
- A61F6/06—Contraceptive devices; Pessaries; Applicators therefor for use by females
- A61F6/14—Contraceptive devices; Pessaries; Applicators therefor for use by females intra-uterine type
- A61F6/142—Wirelike structures, e.g. loops, rings, spirals
- A61F6/144—Wirelike structures, e.g. loops, rings, spirals with T-configuration
Landscapes
- Health & Medical Sciences (AREA)
- Reproductive Health (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Prostheses (AREA)
- Medicinal Preparation (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
The present invention relates to gynecological's medical instruments field, particularly, the present invention relates to a kind of intrauterine implant.Intrauterine implant of the present invention, comprises support (1) and is coated on the pastille diaphragm (3) on support (1).Uterine cavity implant of the present invention, improve significantly implant long-term uterine cavity implant and uterus caused stimulus effects, to uterus Mucous rehabilitation action effect the problem such as the lower and drug-induced systemic effects of oral hormone class, and the effect substantially increased when using stage by stage and personalization level.
Description
Technical field
The present invention relates to gynecological's medical instruments field, particularly, the present invention relates to a kind of intrauterine implant.
Background technology
Intrauterine device (Intrauterinedevice, IUD) early than 1909 for contraception, be that a kind of contraceptive effect is good, safe, easy to use, the long-acting contraception method of economy, reversible action.Within 2002, existing 1.56 hundred million women in World Health Organization's statistics display whole world use IUD, and wherein Asian countries's user occupies the majority, and Chinese user almost accounts for global 2/3, and long-term use certificate understands that its safety can be trusted.
The present invention, on the product and shape basis of intrauterine device, removes the medicine and copper product that play birth control effect, continues to use the mounting system of its safety, increase the membrane structure with estrogen and progestogen medicine, to treat and to prevent the adhesion with cervix uteri in uterine cavity.
Intrauterine adhesion is also known as Asherman syndrome, and after referring to caused by various factors uterine cavity or neck tube basal layer inner film injury, uterine cavity flesh wall and/or neck tube are adhered mutually.Metrosynizesis is common gynecological disease, and basal layer endometrium sustains damage, can produce between uterine cavity inwall fibrous connective tissue be connected, even cause time serious uterine cavity normal configuration disappear, intrauterine adhesion close no longer include lacuna.Metrosynizesis is relevant with uterine neck diseases, repeatedly artificial abortion (particularly induced abortion), postoperative short-term sexual life and operation lack of standardization of performing the operation with uterus.
Hysteroscope is the goldstandard of current intrauterine adhesion diagnosis and the prefered method for the treatment of, but follow-up preventing again does not still have the effective effective ways playing barrier action and carry out adhesion obstruct and promote inner membrance growth in uterine cavity in adhesion treatment.Meanwhile, for the prevention of the postoperative adhesion again of conventional intrauterine surgical, good way is not had yet.The Therapeutic Method of current routine has several as follows:
1. intrauterine device
Current most scholar is using classical way that uterine cavity placement of intrauterine devices after intrauterine adhesion exclusion is adhered as prevention of postoperative for 2 ~ 3 months again.But for being adhered less effective again after severe intrauterine adhesion operation in patients in prevention, can not effectively intercept uterus front and rear wall; And excessive inflammatory reaction may be caused, cause a large amount of inflammatory mediator and urge to be adhered formation release of cytokines, accelerating the postoperative formation be adhered again.
2. balloon expandable method
Commonly use Foley sacculus urinary catheter at present clinically as utricule.But there is retrograde infection, service time is shorter, use is inconvenient, the sacculus water-filling pressure not easily problem such as Accurate Measurement.
3. biogum class
Clinical in preventing the postoperative biogum mainly latest generation hyaluronic derivant-self-crosslinking polysaccharide gel (auto-cross-linkedpolysaccharidesgel, ACPgel) being adhered formation again of intrauterine adhesion at present.The surface of the wound surface after being adhered separation can be rested on for a long time, avoid wound surface to be affixed, inflammation-inhibiting cell migration, the diffusion of restriction Fibrinogen, thus play the effect that prevention of postoperative is adhered formation again.Though ACPgel degradation time has clear improvement compared with HA, but the longest is 72 hours, though in the effect that the commitment of wound healing has prevention to be adhered again, but the wound healing later stage is adhered in the slow process of formation again, the effect of ACPgel is obviously not as good as intrauterine device and Foley sacculus urinary catheter, therefore expect that retention time is longer, more the biogum class of degradation resistant occurs.
4. estrogen
After intrauterine adhesion exclusion routine give oral or injection estrogen and progestogen sequential artificial cycle 2 ~ 3 months or separately the estrogenic measure of application prevention light-certainly, menstruation recovery and reproductive abnormality all obviously improve to be adhered effect in formation again after moderate intrauterine adhesion patient is adhered exclusion.But patient outcome is pessimistic for severe intrauterine adhesion, the postoperative rate that is adhered again can reach more than 50%.Suggest severe intrauterine adhesion patient inner membrance basal layer destroys serious, when react estrogen deficiency, emphasizes whether high estrogen level can cause some to be shortly adhered factor level rising simply, increases the weight of to be adhered and the generation of intimal fibrosis again.In addition, can the estrogen through liver metabolism cannot be determined the bioavailability of remaining inner membrance effective stimulus, and oral administration can produce stimulation to whole body target organ, can aggravate the stimulation of endometriosis focus and breast tumor cell, be unfavorable for the fertility expection that patient is final.Therefore, estrogen effect be adhered again in formation after severe intrauterine adhesion patient is adhered exclusion needs to be inquired into further.Separately, a large-scale Denmark comparative study display, use the women of the oral contraceptive containing a small amount of or minute quantity estradiol, the relative risk that thrombotic apoplexy and myocardial infarction (MI) occur is 1 ~ 2 times of not user.
5. Fiber-hysteroscope is detected and blunt separation art
Intrauterine adhesion patient from postoperative 2 weeks, every within 1 ~ 3 week, to carry out primary fiber hysteroscope detect with mirror under be newbornly loosely adhered band blunt separation art, what be adhered with prevention of postoperative densification is formed again.Problems such as " intrauterine device bring out chronic inflammatory disease, and Foley sacculus urinary catheter causes infecting and incompetence,cervical " that the method does not exist, but still do not solve the problem of prevention and daily obstruct adhesion, and patient compliance is poor.
There are two main problems in these methods above-mentioned: 1, the impact of systemic administration.2, additive method low effect operationally, inconvenience and risk.Analyzed as can be seen from above, keep the screen effect of uterine cavity implant and pass through to increase medicine local sustained release to eliminate hormone medicine systemic administration disadvantage, and pass through the indwelling time and the release medicament categories that control implant, realization has arrange the staged course for the treatment of, can realize the good result of the treatment of uterine cavity implant and prevention metrosynizesis.
Using this kind of uterine cavity implant product as medical apparatus and instruments, the application for the treatment of and prevention metrosynizesis does not also have report.
Summary of the invention
The object of the invention is to, provide a kind of containing estrogen and/or progestogen, the uterine cavity implant that can intercept endometrium contact, overcome the side effect caused thus at Formulations for systemic administration on the one hand; On the other hand, enhance barrier action and stage targetedly, the result of use of targeting medication.
For achieving the above object, intrauterine implant of the present invention, the pastille diaphragm 3 comprising support 1 and be coated on support 1.
According to intrauterine implant of the present invention, described pastille diaphragm 3 is coated on support 1 and forms membrane layer.Further, described pastille diaphragm 3 can also divide some sections to be coated on support 1 to form membrane layer spaced apart.
According to intrauterine implant of the present invention, preferably, described pastille diaphragm 3 integral coating forms membrane body on the outline solid region that support 1 is formed.
According to intrauterine implant of the present invention, further, described support 1 can be T-shaped, and pastille diaphragm 3 is coated is filled in the delta-shaped region formation membrane body formed with end points bottom support 1 two-arm end points and vertical shaft.
Or described support 1 can be γ shape, pastille diaphragm 3 is coated is filled in the delta-shaped region formation membrane body formed with support 1 two-arm end points and bottom end points.
Described support 1 shape can also be the distortion of above-mentioned T-shaped or γ shape, such as, T-shaped or each shape shown in Fig. 6 of ring-type shown in Fig. 1, include but not limited to ring-type Y-shaped, Y-shaped, both arms be ring-type V-shaped, both arms are straight and the γ shape, fork-shaped etc. of sealing.
When above-mentioned support 1 is T-shaped, when γ shape or both distortion, described delta-shaped region forms membrane body, is not limited to the triangle of rule, also comprises the shape of irregular entirety structure triangular in shape, if triangle both sides are concavo-convex staggered structure.Particularly, such as both sides can be dentation, and described profile of tooth can be preferably trapezoidal or circular arc (as shown in Figure 10).
Above-mentioned support 1 can also be annular, and pastille diaphragm 3 is coated is filled in whole annular region.
When described support 1 is annular, as shown in Figure 5, can also but be not limited to the Pear-Shaped of biarc connecting composition, petal or butterfly that four circular arcs form, fan-shaped etc., as required, difform supporter can also be set in annulus.Can also as required, by pastille diaphragm 3 hollow out (as shown in figure 11) in annulus.
According to intrauterine implant of the present invention, described pastille diaphragm 3 contained drug is estrogen, progestogen or both mixture, and preferably, the outer medicine of pastille diaphragm 3 is estrogen, and interior nuclear pharmaceuticals is estrogen, both progestogen mixture.
According to intrauterine implant of the present invention, the nearly cervix uteri end of described intrauterine implant is provided with pastille caudal vertebra 4, and described pastille caudal vertebra 4 contained drug is estrogen, progestogen or both mixture.
According to intrauterine implant of the present invention, when above-mentioned pastille diaphragm 3 integral coating forms membrane body on the outline solid region that support 1 is formed, can also be provided with some pastille inclusion enclaves 2 on support 1, described pastille inclusion enclave 2 thickness is higher than pastille diaphragm 3.This pastille inclusion enclave 2 contained drug is estrogen, progestogen or both mixture, and the outer medicine of described pastille diaphragm 3 is estrogen, and interior nuclear pharmaceuticals is estrogen, both progestogen mixture.
According to intrauterine implant of the present invention, the nearly cervix uteri end of described intrauterine implant can also be provided with pastille caudal vertebra 4, and described pastille caudal vertebra 4 contained drug is estrogen, progestogen or both mixture.Described pastille caudal vertebra 4, rests in cervix uteri, plays the effect preventing cervical adhesion, and increases the convenience of placing and taking out intrauterine implant.
According to intrauterine implant of the present invention, the nearly cervix uteri end of above-mentioned all types of implant can also be provided with tailfiber 5, implant of conveniently taking, and described tailfiber 5 is medical polyester nylon wire.
According to intrauterine implant of the present invention, described support is medical corrosion-resistant metal materials support.Described pastille diaphragm, the material of pastille inclusion enclave and pastille caudal vertebra can be medical anti-adhesive material (such as silicone rubber, politef, ethyl cellulose nylon, medical natural polymer is (as osseocolla, gelatin, sodium alginate, agar, medical chitose (MedicalChitosan chitosan), hyaluronic acid and derivant thereof etc.), medical semisynthetic macromolecule (as cellulose derivative etc.), medical synthesis macromolecule is (as polydextrose acid, polylactic acid, polyglycolic acid, polyester, polydimethylsiloxane (PDMS) material) etc., wherein, be preferably silastic material to make.The diaphragm made can launch in folding and unfolding, and above-mentioned each parts contained drug is estrogen and/or progestogen, slow release in uterine cavity topical, prevents the general action of hormone medicine, plays the barrier action of medical grade silicon rubber material.
The present invention relates to a kind of uterine cavity implant containing estrogen and/or progestogen, improve significantly implant long-term uterine cavity implant and uterus caused stimulus effects, to uterus Mucous rehabilitation action effect the problem such as the lower and drug-induced systemic effects of oral hormone class, and the effect substantially increased when using stage by stage and personalization level.
Intrauterine implant of the present invention, described pastille diaphragm 3 can also be replaced by not pastille diaphragm 7, i.e. intrauterine implant of the present invention, the not pastille diaphragm 7 comprising support 1 and be coated on support 1.
According to intrauterine implant of the present invention, preferably, described not pastille diaphragm 7 integral coating forms membrane body on the outline solid region that support 1 is formed.
According to intrauterine implant of the present invention, further, described support 1 can be T-shaped, and pastille diaphragm 7 is not coated is filled in the delta-shaped region formation membrane body formed with end points bottom support 1 two-arm end points and vertical shaft.
Or described support 1 can be γ shape, pastille diaphragm 7 is not coated is filled in the delta-shaped region formation membrane body formed with support 1 two-arm end points and bottom end points.
Described support 1 shape can also be the distortion of above-mentioned T-shaped or γ shape, such as, T-shaped or each shape shown in Fig. 6 of ring-type as shown in Figure 1, include but not limited to ring-type Y-shaped, Y-shaped, both arms be ring-type V-shaped, both arms are straight and the γ shape, fork-shaped etc. of sealing.Wherein, the pastille inclusion enclave 2 of above-mentioned each figure, pastille diaphragm 3 and pastille caudal vertebra 4 by not pastille inclusion enclave 6, not pastille diaphragm 7 and not pastille caudal vertebra 8 replace.
When above-mentioned support 1 is T-shaped, when γ shape or both distortion, described delta-shaped region forms membrane body, is not limited to the triangle of rule, also comprises the shape of irregular entirety structure triangular in shape, if triangle both sides are concavo-convex staggered structure.Particularly, such as both sides can be dentation, and described profile of tooth can be preferably trapezoidal or circular arc (as shown in Figure 10, each pastille part all not pastille).
Above-mentioned support 1 can also be annular, and pastille diaphragm 7 is not coated is filled in whole annular region.
When described support 1 is annular, as shown in Figure 5, can also but be not limited to the Pear-Shaped of biarc connecting composition, petal or butterfly that four circular arcs form, fan-shaped etc., as required, difform supporter can also be set in annulus.Can also as required, by not pastille diaphragm 7 hollow out (as shown in figure 11, pastille part all not pastille) in annulus.
According to intrauterine implant of the present invention, when above-mentioned not pastille diaphragm 7 integral coating forms membrane body on the outline solid region that support 1 is formed, can also be provided with some not pastille inclusion enclaves 6 on support 1, described not pastille inclusion enclave 6 thickness is higher than not pastille diaphragm 7.
According to intrauterine implant of the present invention, the nearly cervix uteri end of described intrauterine implant can also be provided with not pastille caudal vertebra 8, rests in cervix uteri, plays the effect preventing cervical adhesion, and increases the convenience of placing and taking out intrauterine implant.Tailfiber 5 can also be arranged conveniently to take simultaneously.
The material of above-mentioned not pastille inclusion enclave 6, not pastille diaphragm 7 of the present invention and not pastille caudal vertebra 8, identical with pastille caudal vertebra 4 with pastille inclusion enclave 2, pastille diaphragm 3, be only not containing any medicine.
The difference of not pastille intrauterine implant of the present invention and pastille intrauterine implant is, pastille inclusion enclave 2 is replaced by not pastille inclusion enclave 6, and pastille diaphragm 3 is replaced by not pastille diaphragm 7, and pastille caudal vertebra 4 is replaced by not pastille caudal vertebra 8.
The not uterine cavity implant of drug containing, except the physical barriers effect having pastille uterine cavity implant to play, advantage easy to use, due to not drug containing, on existing doctors experience medication basis, external drug treatment can be carried out by the practical situation of the person of being combined, and personalization adjustment is carried out to dosage and operational phase; Still the repairing accelerant effect to Uterine mucosa adhesion can be reached.
To sum up, the invention has the advantages that: 1, have physical barriers effect, be convenient to treat in uterine cavity, the adhesion of cervix uteri; 2, due to containing estrogen and/or progestogen, endometrium is had to the impact accelerating rehabilitation; Decrease the side reaction of systemic administration; 3, the uterine cavity implant of drug containing can not adjust the occupation mode of medicine flexibly according to the state of an illness and progress; 4, owing to including medicine components difference, can be prepared as respectively and only contain estrogen, containing estrogen and progestogen mixture, the several types only containing progestogen; In the cycle of every 30 days, according to the situation that endometrium is repaired, different use orders, collocation order can be selected, personalized treatment can be accomplished; 5, conventional intrauterine is performed the operation, more convenient as preventative placement, the generation of metrosynizesis situation can be lowered greatly.
Accompanying drawing explanation
Fig. 1 intrauterine implant structure of the present invention schematic diagram (T annular).
Fig. 2 intrauterine implant structure of the present invention schematic diagram (T-shaped).
Fig. 3 intrauterine implant structure of the present invention schematic diagram (γ shape).
Fig. 4 intrauterine implant structure of the present invention schematic diagram (annular).
The schematic diagram of Fig. 5 intrauterine implant of the present invention annular related variation.
The schematic diagram of Fig. 6 intrauterine implant of the present invention T-shaped or γ shape related variation.
Fig. 7 intrauterine implant of the present invention places taking-up instrument.
Fig. 8 intrauterine implant structure of the present invention schematic diagram (T-shaped membrane body form)
Fig. 9 intrauterine implant structure of the present invention schematic diagram (T-shaped segmentation membrane body form)
Figure 10 intrauterine implant structure of the present invention schematic diagram (T-shaped dentation membrane body form)
Figure 11 intrauterine implant structure of the present invention schematic diagram (annular hollow out membrane body form)
Figure 12 intrauterine implant structure of the present invention schematic diagram (not pastille)
Accompanying drawing identifies
1, support 2, pastille inclusion enclave 3, pastille diaphragm
4, pastille caudal vertebra 5, tailfiber 6, not pastille inclusion enclave
7, not pastille diaphragm 8, not pastille caudal vertebra
Detailed description of the invention
In order to understand technical scheme of the present invention better, below in conjunction with accompanying drawing, implementation step of the present invention is further described.
Intrauterine implant of the present invention, the pastille diaphragm 3 comprising support 1 and be coated on support 1.
According to intrauterine implant of the present invention, as shown in Figure 8, described pastille diaphragm 3 is coated on support 1 and forms membrane layer.Further, as shown in Figure 9, described pastille diaphragm 3 can also divide some sections to be coated on support 1 to form membrane layer spaced apart.
According to intrauterine implant of the present invention, preferably, described pastille diaphragm 3 integral coating forms membrane body on the outline solid region that support 1 is formed.
As illustrated in fig. 1 and 2, intrauterine implant of the present invention, described support 1 can be T-shaped, or according to the ring-type T-shaped that T-shaped is out of shape, pastille diaphragm 3 is coated is filled in the delta-shaped region formation membrane body formed with end points bottom support 1 two-arm end points and vertical shaft.
As shown in Figure 3, intrauterine implant of the present invention, described support 3 can be γ shape, and support two-arm and ring bodies both sides are provided with pastille inclusion enclave 2, and pastille diaphragm 3 parcel is filled in the Delta Region formed with support two-arm end points and ring bodies lower extreme point.Described support shape can also be above-mentioned T-shaped, T annular or the distortion of γ shape, as shown in Figure 6, include but not limited to Y word annular, Y-shaped, both arms be ring-type V-shaped, both arms are straight and the γ shape, fork-shaped etc. of sealing.Pastille caudal vertebra 4 is provided with bottom the implant of above-mentioned each shape.Described pastille caudal vertebra 4 preferred material is silica gel, rests in cervix uteri, plays the effect preventing cervical adhesion, and increases the convenience of placing and taking out intrauterine implant.
As shown in Figure 4, according to intrauterine implant of the present invention, it can also be annular, pastille diaphragm 3 is coated is filled in whole annular region, as shown in Figure 5, described ring support, can also but be not limited to the petal or butterfly, fan-shaped etc. of the Pear-Shaped of biarc connecting composition, four circular arcs composition, as required, difform supporter can also be set in annulus.
The nearly cervix uteri end of above-mentioned each intrauterine implant also can be provided with pastille caudal vertebra 4.Described pastille caudal vertebra 4 contained drug is estrogen, progestogen or both mixture.
Above-mentioned pastille diaphragm 3 contained drug is estrogen, progestogen or both mixture.Particularly preferably, preparing in pastille diaphragm 3 process, designing peripheral medicine is estrogen, and interior nuclear pharmaceuticals is estrogen, both progestogen mixture.
When above-mentioned pastille diaphragm 3 integral coating forms membrane body on the outline solid region that support 1 is formed, some pastille inclusion enclaves 2 can also be provided with on support 1, this pastille inclusion enclave 2 contained drug is estrogen, progestogen or both mixture, and the outer medicine of described pastille diaphragm 3 is estrogen, interior nuclear pharmaceuticals is estrogen, both progestogen mixture.
Intrauterine implant of the present invention is provided with tailfiber 5 at nearly cervix uteri end, can conveniently take, and described tailfiber 5 is medical polyester nylon wire.
Intrauterine implant of the present invention, embody rule and operation as follows:
According to intrauterine implant of the present invention, when making pastille inclusion enclave, pastille diaphragm or pastille caudal vertebra, can be as required, after described estrogen, progestogen or the two mixture are mixed homogeneously with raw material (medical anti-adhesive material), molding, fill with mould, make corresponding pastille inclusion enclave, pastille diaphragm or pastille caudal vertebra.
The medication amount put into is added based on general knowledge known in this field, and preferably, each medicine requires that the concentration of release sees the following form 1 every day.
Table 1 medicine burst size every day
| Medicine | Every day requires burst size |
| Estradiol | 30 mg/day and following |
| Natural progesterone | 40 micro-grams/day and following |
| Levonorgestrel | 20 micro-grams/day and following |
1, according to metrosynizesis and loosen postoperative situation, select only to contain estrogen, only containing progestogen or the intrauterine implant containing estrogen and progestogen mixture, generally only contain estrogenic type in just postoperative selection, use 30 days, then check, optionally with or without taking a turn for the better and the judgement of doctor, then select only containing estrogen or only containing progestogen or the intrauterine implant containing estrogen and progestogen mixture.
2, judge according to doctor, select suitable uterine cavity implant to be a treatment cycle with 30 days, can stop in advance and change the intrauterine implant of variety classes (different pharmaceutical).
3, according to the judgement of doctor, one or more treatment cycle can be selected, to reach treatment and preventive effect.
4, laying method as IUD laying method, but tailfiber 5 to be extended to cervix uteri mouth from intracavity.Place taking-up instrument as shown in Figure 7.
Intrauterine implant of the present invention, described pastille inclusion enclave 2, pastille diaphragm 3 and pastille caudal vertebra 4 can be replaced by not pastille inclusion enclave 6, not pastille diaphragm 7 and not pastille caudal vertebra 8 respectively, make intrauterine implant entirety of the present invention not drug containing.Wherein one such as shown in Figure 12.
Intrauterine implant embody rule and the operation of not pastille of the present invention are as follows:
According to intrauterine implant of the present invention, directly using raw material (medical anti-adhesive material), molding when making, filling with mould, make accordingly not pastille inclusion enclave, not pastille diaphragm or not pastille caudal vertebra.
1, according to metrosynizesis and loosen postoperative situation, selecting this intrauterine implant, use 30 days, then check, optionally with or without taking a turn for the better and the judgement of doctor, then selecting new this intrauterine implant.At therapeutic process simultaneously, doctor should assist with external drug (oral or external) to reach therapeutic effect, and the medication amount that use is based on general knowledge known in this field.
2, judge according to doctor, select suitable uterine cavity implant to be a treatment cycle with 30 days, can stop in advance and change the intrauterine implant of variety classes (different pharmaceutical).
3, according to the judgement of doctor, one or more treatment cycle can be selected, to reach treatment and preventive effect.
4, laying method as IUD laying method, but tailfiber 5 to be extended to cervix uteri mouth from intracavity.Place taking-up instrument as shown in Figure 7.
It should be noted last that, above embodiment is only in order to illustrate technical scheme of the present invention and unrestricted.Although with reference to embodiment to invention has been detailed description, those of ordinary skill in the art is to be understood that, modify to technical scheme of the present invention or equivalent replacement, do not depart from the spirit and scope of technical solution of the present invention, it all should be encompassed in the middle of right of the present invention.
Claims (13)
1. an intrauterine implant, is characterized in that, described intrauterine implant comprises support (1) and is coated on the pastille diaphragm (3) on support (1); Wherein, described pastille diaphragm (3) integral coating forms membrane body on the outline solid region that support (1) is formed; The material of described pastille diaphragm is one or more in silicone rubber, politef, ethyl cellulose nylon, osseocolla, gelatin, sodium alginate, agar, medical chitose, hyaluronic acid and derivant thereof, cellulose derivative, polydextrose acid, polylactic acid, polyglycolic acid, polyester and polydimethylsiloxane.
2. intrauterine implant according to claim 1, it is characterized in that, described support (1) is T-shaped, and pastille diaphragm (3) is coated is filled in the delta-shaped region formation membrane body formed with end points bottom support (1) two-arm end points and vertical shaft.
3. intrauterine implant according to claim 1, it is characterized in that, described support (1) is γ shape, and pastille diaphragm (3) is coated is filled in the delta-shaped region formation membrane body formed with support (1) two-arm end points and bottom end points.
4., according to the arbitrary described intrauterine implant of claim 1-3, it is characterized in that, described pastille diaphragm (3) contained drug is estrogen, progestogen or both mixture.
5. according to the arbitrary described intrauterine implant of claim 1-3, it is characterized in that, the nearly cervix uteri end of described intrauterine implant is provided with pastille caudal vertebra (4), and described pastille caudal vertebra (4) contained drug is estrogen, progestogen or both mixture.
6. according to the arbitrary described intrauterine implant of claim 1-3, it is characterized in that, described support (1) is also provided with some pastille inclusion enclaves (2), this pastille inclusion enclave (2) contained drug is estrogen, progestogen or both mixture, the outer medicine of described pastille diaphragm (3) is estrogen, and interior nuclear pharmaceuticals is estrogen, both progestogen mixture.
7. intrauterine implant according to claim 6, is characterized in that, the nearly cervix uteri end of described intrauterine implant is provided with pastille caudal vertebra (4), and described pastille caudal vertebra (4) contained drug is estrogen, progestogen or both mixture.
8. an intrauterine implant, is characterized in that, described intrauterine implant comprises support (1) and is coated on the not pastille diaphragm (7) on support (1); Wherein, described not pastille diaphragm (7) integral coating forms membrane body on the outline solid region that support (1) is formed; The material of described pastille diaphragm is one or more in silicone rubber, politef, ethyl cellulose nylon, osseocolla, gelatin, sodium alginate, agar, medical chitose, hyaluronic acid and derivant thereof, cellulose derivative, polydextrose acid, polylactic acid, polyglycolic acid, polyester and polydimethylsiloxane.
9. intrauterine implant according to claim 8, it is characterized in that, described support (1) is T-shaped, and pastille diaphragm (7) is not coated is filled in the delta-shaped region formation membrane body formed with end points bottom support (1) two-arm end points and vertical shaft.
10. intrauterine implant according to claim 8, it is characterized in that, described support (1) is γ shape, and pastille diaphragm (7) is not coated is filled in the delta-shaped region formation membrane body formed with support (1) two-arm end points and bottom end points.
11. intrauterine implants according to claim 8, is characterized in that, described support (1) is annular, and pastille diaphragm (7) is not coated is filled in whole annular region.
12.-11 arbitrary described intrauterine implants according to Claim 8, is characterized in that, described support (1) is also provided with some not pastille inclusion enclaves (6).
13.-11 arbitrary described intrauterine implants according to Claim 8, it is characterized in that, the nearly cervix uteri end of described intrauterine implant is provided with not pastille caudal vertebra (8).
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310003855.5A CN103784244B (en) | 2012-10-30 | 2013-01-06 | A kind of intrauterine implant |
| PCT/CN2013/001654 WO2014106315A1 (en) | 2013-01-06 | 2013-12-30 | Intrauterine implant |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210424513.6 | 2012-10-30 | ||
| CN2012104245136 | 2012-10-30 | ||
| CN201210424513 | 2012-10-30 | ||
| CN201310003855.5A CN103784244B (en) | 2012-10-30 | 2013-01-06 | A kind of intrauterine implant |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103784244A CN103784244A (en) | 2014-05-14 |
| CN103784244B true CN103784244B (en) | 2016-03-23 |
Family
ID=51063017
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310003855.5A Active CN103784244B (en) | 2012-10-30 | 2013-01-06 | A kind of intrauterine implant |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN103784244B (en) |
| WO (1) | WO2014106315A1 (en) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105078642B (en) * | 2014-05-14 | 2018-07-24 | 吴江永元生物科技有限公司 | A kind of uterus implant |
| KR102444092B1 (en) * | 2014-08-19 | 2022-09-16 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Implants for localized drug delivery and methods of use thereof |
| CN105982779A (en) * | 2015-02-10 | 2016-10-05 | 刘雯倩 | Contraceptive ring |
| CN104998343A (en) * | 2015-07-24 | 2015-10-28 | 严聪颖 | Medicine-prefilled and sustained-release apparatus for uterus uses and implantation method |
| WO2017184669A1 (en) * | 2016-04-20 | 2017-10-26 | Duke University | Intrauterine adhesion barrier device and method of use |
| CN105903092A (en) * | 2016-06-23 | 2016-08-31 | 刘芸 | Uterus implant and implanting system for same |
| CN107951550A (en) * | 2017-12-14 | 2018-04-24 | 易浦润（上海）生物技术有限公司 | A kind of degradable inner membrane of uterine cavity implant system |
| ES2930330T3 (en) * | 2018-04-19 | 2022-12-12 | Yipurun Shanghai Biotechnology Co Ltd | Elastic membrane having a function of reactivation of the endometrial basal layer in a uterine cavity and preparation method of the elastic membrane |
| CN108852569B (en) * | 2018-05-21 | 2020-10-16 | 柏为（武汉）医疗科技股份有限公司 | Degradable supporting diaphragm device for preventing and treating intrauterine adhesion |
| CN109602535B (en) * | 2019-02-15 | 2024-03-22 | 易浦润（上海）生物技术有限公司 | Intrauterine membrane placement device and placement method thereof |
| CN110721393A (en) * | 2019-10-28 | 2020-01-24 | 易浦润（上海）生物技术有限公司 | Uterine stent and preparation method thereof |
| US11173291B2 (en) | 2020-03-20 | 2021-11-16 | The Regents Of The University Of California | Implantable drug delivery devices for localized drug delivery |
| US11338119B2 (en) | 2020-03-20 | 2022-05-24 | The Regents Of The University Of California | Implantable drug delivery devices for localized drug delivery |
| US11344526B2 (en) | 2020-03-20 | 2022-05-31 | The Regents Of The University Of California | Implantable drug delivery devices for localized drug delivery |
| CN114246725B (en) * | 2021-12-16 | 2024-01-12 | 湖州市妇幼保健院 | Intrauterine device with anti-adhesion material |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7252839B2 (en) * | 2002-09-18 | 2007-08-07 | Schering Oy | Delivery system and a manufacturing process of a delivery system |
| CN101229074A (en) * | 2008-02-27 | 2008-07-30 | 徐大宝 | Asherman's syndrom curing equipment |
| CN101278872A (en) * | 2007-04-05 | 2008-10-08 | 辽宁爱母医疗科技有限公司 | Nano memory alloy intrauterine device |
| CN201161050Y (en) * | 2008-02-27 | 2008-12-10 | 程春霞 | Instrument for treating uterine cavity synechiac |
| CN201182672Y (en) * | 2006-04-14 | 2009-01-21 | 辽宁爱母医疗科技有限公司 | Novel nano memory alloy intrauterine device |
| CN201618299U (en) * | 2009-12-23 | 2010-11-03 | 中国医学科学院生物医学工程研究所 | Intrauterine medicine slow-release device |
| CN201888869U (en) * | 2010-10-29 | 2011-07-06 | 湖南省计划生育研究所 | T-shaped intrauterine contraceptive device |
| CN202044643U (en) * | 2011-03-11 | 2011-11-23 | 东南大学 | Drug membrane-covered stent for preventing and curing intrauterine adhesion |
| CN102648868A (en) * | 2012-02-29 | 2012-08-29 | 徐大宝 | Intrauterine adhesion prevention and cure device |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050171569A1 (en) * | 2000-04-25 | 2005-08-04 | Impres Medical, Inc. | Method and apparatus for creating intrauterine adhesions |
| US20060089658A1 (en) * | 2004-10-21 | 2006-04-27 | Harrington Douglas C | Method and apparatus for treating abnormal uterine bleeding |
-
2013
- 2013-01-06 CN CN201310003855.5A patent/CN103784244B/en active Active
- 2013-12-30 WO PCT/CN2013/001654 patent/WO2014106315A1/en active Application Filing
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7252839B2 (en) * | 2002-09-18 | 2007-08-07 | Schering Oy | Delivery system and a manufacturing process of a delivery system |
| CN201182672Y (en) * | 2006-04-14 | 2009-01-21 | 辽宁爱母医疗科技有限公司 | Novel nano memory alloy intrauterine device |
| CN101278872A (en) * | 2007-04-05 | 2008-10-08 | 辽宁爱母医疗科技有限公司 | Nano memory alloy intrauterine device |
| CN101229074A (en) * | 2008-02-27 | 2008-07-30 | 徐大宝 | Asherman's syndrom curing equipment |
| CN201161050Y (en) * | 2008-02-27 | 2008-12-10 | 程春霞 | Instrument for treating uterine cavity synechiac |
| CN201618299U (en) * | 2009-12-23 | 2010-11-03 | 中国医学科学院生物医学工程研究所 | Intrauterine medicine slow-release device |
| CN201888869U (en) * | 2010-10-29 | 2011-07-06 | 湖南省计划生育研究所 | T-shaped intrauterine contraceptive device |
| CN202044643U (en) * | 2011-03-11 | 2011-11-23 | 东南大学 | Drug membrane-covered stent for preventing and curing intrauterine adhesion |
| CN102648868A (en) * | 2012-02-29 | 2012-08-29 | 徐大宝 | Intrauterine adhesion prevention and cure device |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014106315A1 (en) | 2014-07-10 |
| CN103784244A (en) | 2014-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103784244B (en) | A kind of intrauterine implant | |
| CN105078642B (en) | A kind of uterus implant | |
| Quarterman et al. | Evolution of drug-eluting biomedical implants for sustained drug delivery | |
| ES2930330T3 (en) | Elastic membrane having a function of reactivation of the endometrial basal layer in a uterine cavity and preparation method of the elastic membrane | |
| RU2542779C2 (en) | Birth control technique used as and when necessary | |
| ES2561823T3 (en) | Contraception method once a month | |
| JP2001524124A (en) | Vaginal drug delivery device for administration of testosterone and testosterone precursor | |
| NO316707B1 (en) | Intravaginal drug delivery device, method of preparation thereof and use | |
| Weber et al. | The success of 6-month stenting in endonasal frontal sinus surgery | |
| CN103417272B (en) | A kind of medicine distribution type uterus support | |
| das Neves et al. | Women-specific routes of administration for drugs: A critical overview | |
| CN103637836A (en) | Intrauterine adhesion prevention and treatment device | |
| CN103301558B (en) | Inductive uterine slow release system | |
| CN109568670A (en) | A kind of hydrogel and preparation method thereof of endometrial impairment reparation | |
| CN109513097A (en) | A kind of two-tube balloon-stent for preventing and treating Asherman's syndrom | |
| Tejuja | Use of subcutaneous Silastic capsules for long-term steroid contraception | |
| CN202044643U (en) | Drug membrane-covered stent for preventing and curing intrauterine adhesion | |
| JP2018516889A (en) | Long-acting drug delivery device and its use in contraception | |
| CN201618299U (en) | Intrauterine medicine slow-release device | |
| Goldstuck et al. | Prevention of intrauterine contraceptive device expulsion and intolerance: Determination of the anchor mechanism | |
| CN203341802U (en) | Induction-type uterine cavity delay release system | |
| Urbán-Morlán et al. | New developments in intrauterine drug delivery systems and devices | |
| CN104203169B (en) | Comprising the pessary of the reagent of the release of meloxicam and the described active component of adjustment, it can be used as the contraceptive used continuously in women | |
| CN203539420U (en) | Medicine-distribution type uterus stent | |
| CN2525971Y (en) | Pessary of slow-released mifepristone |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20160112 Address after: 215200 south side of Yunlong Road West, Wujiang economic and Technological Development Zone, Suzhou, Jiangsu 215200 Applicant after: Wujiang Yongyuan Biotechnology Co., Ltd. Address before: 100021, Beijing, Chaoyang District, Jinsong agricultural light East 13 Building No. 1607 Applicant before: Rao Yong |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |